<scp>SGLT2</scp> inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in <scp>SMARTEST</scp> , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

This decentralised RRCT in newly onset T2D demonstrates a highly feasible option for large-scale trials in the primary care setting, enabling representative participant recruitment. Blinded interim analyses showed a low risk of MACE or death, but unexpectedly high rates of microvascular complications. Study completion is event-driven and is expected by January 2026. The study will challenge or reinforce the current metformin paradigm in early T2D. (EUDRA-CT number 2019-001046-17; EU number 2024-516228-33-00; ClinicalTrials.gov Identifier: NCT03982381).

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2025-11-28
DOI
https://doi.org/10.1111/dom.70320
Citations
1
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
1.29
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Stefan Jansson, Vagia Patsoukaki, Anna Norhammar, Jan W. Eriksson et al.
1 citations
Diabetes Obesity and Metabolism
Diabetes Treatment and Management
1.29
article

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST , a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Stefan Jansson, Vagia Patsoukaki, Anna Norhammar, Jan W. Eriksson, Annette Nilsson, Sheyda Sofizadeh, Louise Bennet, M. Lundqvist, Björn Eliasson, Elisabet Granstam, Giovanni Fanni, Daniel Lindholm, Johan Sundström, Olov Rolandsson, Karin Rådholm
article en
1 citations

Abstract

This decentralised RRCT in newly onset T2D demonstrates a highly feasible option for large-scale trials in the primary care setting, enabling representative participant recruitment. Blinded interim analyses showed a low risk of MACE or death, but unexpectedly high rates of microvascular complications. Study completion is event-driven and is expected by January 2026. The study will challenge or reinforce the current metformin paradigm in early T2D. (EUDRA-CT number 2019-001046-17; EU number 2024-516228-33-00; ClinicalTrials.gov Identifier: NCT03982381).

Diabetes Obesity and MetabolismVol. 28(2)
Linköping University (SE), Uppsala University (SE), Uppsala University Hospital (SE), Lund University (SE), Örebro University (SE), Karolinska Institutet (SE), Department of Medical Sciences (RU), Uddevalla sjukhus (SE), Södertälje Sjukhus (SE), Primary Health Care (QA), University of Gothenburg (SE), Umeå University (SE)
Openalex Percentile: Top 13%
Diabetes Treatment and Management
1.29
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.